¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"turn down ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • optimal ratio
    ÃÖÀûºñ
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • phase ratio
    »óºñ
  • primary sex ratio
    ÀÏÂ÷¼ººñ
  • rate ratio
    ºñÀ²ºñ
  • ratio
    1. ºñ 2. ºñÀ², À²
  • ratio scale
    ºñÀ²Ã´µµ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • respiratory exchange ratio
    È£Èí±³È¯ºñÀ²
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • risk ratio
    À§Çèºñ
  • standardized mortality ratio
    Ç¥ÁØÈ­»ç¸Áºñ
  • standardized rate ratio
    Ç¥ÁØÈ­ºñÀ²ºñ
  • stopping power ratio
    ÀúÁö´Éºñ
  • survival ratio
    »ýÁ¸ºñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • mixing water ratio
    ¹°È¥ÇÕºñ
  • monocyte lymphocyte ratio
    ´ÜÇÙ±¸¸²ÇÁ±¸ºñÀ²
  • mortality ratio
    »ç¸Áºñ
  • noise ratio
    ÀâÀ½ºñ
  • nuclear-cytoplasmic ratio
    ÇÙ¼¼Æ÷Áúºñ
  • odds ratio
    ±³Â÷ºñ
  • optimal ratio
    ÃÖÀûºñ
  • optimal proportion ratio
    (¢¡optimal ratio) ÃÖÀûºñ
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • phase ratio
    »óºñ
  • primary sex ratio
    ÀÏÂ÷¼ººñ
  • ratio
    ºñ, À²
  • rate ratio
    ºñÀ²ºñ
  • ratio scale
    ºñôµµ
  • respiratory exchange ratio
    È£Èí±³È¯ºñÀ²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • extraction ratio
    ÃßÃâ·ü(õÎõóëÒ).
  • gas exchange ratio
    °¡½º±³È¯ºñÀ²(ÎßüµÝï×Ë).
  • gyromagnetic ratio
    ȸÀü Àڱ⠺ñÀ²
  • heart lung ratio =HLR
    ½ÉÆó°è¼ö(ãýøËÌõâ¦), ½ÉÈä(°û)ºñ(ãýýØÎ¬Ýï).
  • hydrodynamic ratio
    ¼ö·ÂÇÐ(Àû) ºñÀ²
  • immunoglobulin G CSF/serum ratio
    ¸é¿ª±Û·ÎºÒ¸° G ³úô¼ö¾×/Ç÷û ºñ(À²)
  • innervation ratio
    ½Å°æÁö¹èºñ(¡­Ýï).
  • inspiratory expiratory ratio
    ÈíÈ£±â´ëºñ.
  • insulin-to-glucose ratio
    Àν¶¸°Æ÷µµ´çºñÀ²
  • ketogenic antiketogenic ratio
    ÄÉÅæÇ×ÄÉÅæ ºñÀ².
  • l/s ratio
    L/S ºñ(¡­Ýï)
  • magnetization transfer ratio (MTR)
    ÀÚÈ­ Àü´Þ ºñÀ²
  • marriage-divorce ratio
    °áÈ¥-ÀÌÈ¥À²(Ë­Ì´ËöÌ´Ëô).
  • mendelian ratio
    ¸àµ¨·ü(¡­ëÏ).
  • mendelian ratio
    ¸àµ¨·ü(¡­ëÏ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
L/P lactate/pyruvate [ratio]; liver plasma [concentration]; lymph/plasma [ratio]
LSR lanthanide shift reagent; lecithin/ sphingomyelin ratio; left superior rectus [muscle]; liver/spleen...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
TR recovery time; rectal temperature; repetition time; residual tuberculin; terminal repeat; tetrazoliu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ER Enhancement Ratio
FCR Feed conversion ratio
FR Fixed Ratio
FR1 Fixed Ratio 1
FR10 Fixed Ratio 10
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
nucleolar-nuclear ratio Ratio of volume of nucleolus to volume of nucleus, usually increased in malignant neoplasms.
(05 Mar 2000)
nutritive ratio The ratio or proportion of digestible protein to digestible non-nitrogenous nutrients in a ration for livestock.
(05 Mar 2000)
systolic/diastolic ratio A calculation from pulsed Doppler ultrasound determinations of blood flow velocities that reflects intrinsic resistance in an arterial blood vessel.
(05 Mar 2000)
international normalised ratio System established by the world health organization and the international committee on thrombosis and haemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardised using the international sensitivity index for the particular test reagent/instrument combination used.
(12 Dec 1998)
IRI/G ratio The ratio of immunoreactive insulin to serum or plasma glucose; in hypoglycaemic states a ratio of less than 0.3 is usual with the exception of the hypoglycaemia due to insulinoma, where the ratio is often higher than 0.3.
(05 Mar 2000)
odds ratio <epidemiology> A comparison of the presence of a risk factor for disease in a sample of diseased subjects and non diseased controls. The number of people with disease who were exposed to a risk factor ( I.e. ) over those with disease who were not exposed ( Io ) divided by those without disease who were exposed ( Ne ) over those without who were not exposed ( No ). Thus OR=(I.e./Io)/(Ne/No)= I.e. No / Io Ne. This measure should be used for case control studies where we retrospectively look at risks in those with and without disease. Also known as exposure odds ratio.
(05 Dec 1998)
therapeutic ratio The ratio of the maximally tolerated dose of a drug to the minimal curative or effective dose; LD50 divided by ED50.
(05 Mar 2000)
tritium-breeding ratio <radiobiology> The amount of tritium generated by the breeding blanket of a D-T fusion reactor, divided by the amount of tritium burned in the reactor. A tritium breeding ration greater than unity is necessary for self-sufficient fueling.
(09 Oct 1997)
exposure odds ratio <epidemiology> See Odds ratio.
(05 Dec 1998)
extraction ratio The fraction of a substance removed from the blood flowing through the kidney; it is calculated from the formula (A -V)/A, where A and V, respectively, are the concentrations of the substance in arterial and renal venous plasma.
(05 Mar 2000)
K:A ratio <abbreviation> Ketogenic-antiketogenic ratio.
(05 Mar 2000)
ketogenic-antiketogenic ratio The proportion between substances that form ketones in the body and those that form d-glucose.
(05 Mar 2000)
zeta sedimentation ratio The ratio of the zetacrit to the haematocrit, normally 0.41 to 0.54 (41 to 54%); it is a sensitive indicator of the erythrocyte sedimentation rate (ESR) and, unlike the latter, is unaffected by anaemia, which tends to elevate the ESR.
(05 Mar 2000)
fertility ratio A measure of the fertility of a population based on the female population in the child-bearing age-group, defined as ages 15-49 years.
(05 Mar 2000)
flux ratio The ratio of the two unidirectional fluxes through a particular boundary layer or membrane.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • run down
    (°ÇÀüÁö°¡) ´ÙÇÏ´Ù; ã¾Æ³»´Ù
  • sell down the river
    ¹è¹ÝÇÏ´Ù
  • set down
    Àû¾îµÎ´Ù; Âø·ú½ÃŰ´Ù
  • settle down
    Á¤ÂøÇÏ´Ù
  • strike down
    Ãļ­ ¾²·¯¶ß¸®´Ù; Á×ÀÌ´Ù
  • swan's-down
    ¹éÁ¶ÀÇ ¼ØÅÐ
  • take down
    ³»¸®´Ù; Çæ´Ù; ±â·ÏÇÏ´Ù
  • tear down
    ºÎ¼ö´Ù
  • up-and-down
    ¿À¸£³»¸®´Â
  • upside-down
    °Å²Ù·ÎÀÇ
  • Down's syndrome
    ´Ù¿î ÁõÈıº(Mongolism)
  • change-down
    (ÀÚµ¿Â÷µîÀÇ ±â¾î¸¦)Àú¼ÓÀ¸·Î ¹Ù²Ù±â
  • climb-down
    ±â¾î³»¸²;(Á¤¼¼°¡ ºÒ¸®ÇÏ´Ù°í º¸°í ÁÖÀå µîÀ»)¹ö¸²;¾çº¸;(¼º¸íµîÀÇ)öȸ
  • down
    ¼ØÅÐ;¹è³»ÅÐ;¾ð´ö;»ç±¸;¹ØÀ¸·Î;¾Æ·¡ÂÊ¿¡;°¡¶ó¾É¾Æ;ÇÏ·ù¿¡;~À» µû¶ó¼­;³»·Á°¡´Â
  • down east
    (¹Ì)µ¿ºÎ ¿¬¾ÈÁö¹æÀ¸·Î(¿¡¼­,ÀÇ);(ƯÈ÷)Maine ÁÖ·Î(¿¡¼­,ÀÇ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á